DK1119630T3 - Nukleinsyrekonstruktioner til genetisk immunisering - Google Patents

Nukleinsyrekonstruktioner til genetisk immunisering

Info

Publication number
DK1119630T3
DK1119630T3 DK99963869T DK99963869T DK1119630T3 DK 1119630 T3 DK1119630 T3 DK 1119630T3 DK 99963869 T DK99963869 T DK 99963869T DK 99963869 T DK99963869 T DK 99963869T DK 1119630 T3 DK1119630 T3 DK 1119630T3
Authority
DK
Denmark
Prior art keywords
nucleic acid
acid constructs
molecules
genetic immunization
sequence encoding
Prior art date
Application number
DK99963869T
Other languages
Danish (da)
English (en)
Inventor
Deborah L Fuller
James T Fuller
Original Assignee
Powderject Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Powderject Vaccines Inc filed Critical Powderject Vaccines Inc
Application granted granted Critical
Publication of DK1119630T3 publication Critical patent/DK1119630T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK99963869T 1998-11-05 1999-11-05 Nukleinsyrekonstruktioner til genetisk immunisering DK1119630T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10716998P 1998-11-05 1998-11-05

Publications (1)

Publication Number Publication Date
DK1119630T3 true DK1119630T3 (da) 2006-05-15

Family

ID=22315199

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99963869T DK1119630T3 (da) 1998-11-05 1999-11-05 Nukleinsyrekonstruktioner til genetisk immunisering

Country Status (13)

Country Link
EP (1) EP1119630B1 (es)
JP (1) JP2002528123A (es)
AT (1) ATE315658T1 (es)
AU (1) AU775939B2 (es)
CA (1) CA2349505A1 (es)
CY (1) CY1105600T1 (es)
DE (1) DE69929470T2 (es)
DK (1) DK1119630T3 (es)
ES (1) ES2257879T3 (es)
IL (1) IL142980A0 (es)
NZ (1) NZ512078A (es)
PT (1) PT1119630E (es)
WO (1) WO2000026385A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6660842B1 (en) 1994-04-28 2003-12-09 Tripep Ab Ligand/receptor specificity exchangers that redirect antibodies to receptors on a pathogen
US6933366B2 (en) 1996-12-27 2005-08-23 Tripep Ab Specificity exchangers that redirect antibodies to bacterial adhesion receptors
DE60017165T2 (de) 1999-10-11 2006-01-12 Felton International, Inc., Lenexa Universelle antiinfektionsschutzvorrichtung für nadellose injektoren
US7887506B1 (en) 1999-11-23 2011-02-15 Pulse Needlefree Systems, Inc. Safety mechanism to prevent accidental patient injection and methods of same
CA2413546C (en) * 2000-06-22 2011-06-14 Celltech Pharmaceuticals Limited Modification of hepatitis b core antigen
PL364788A1 (en) * 2000-09-19 2004-12-13 Tripep Ab Ligand/receptor specificity exchangers that redirect antibodies to receptors on a pathogen
EP1392357A2 (en) * 2001-05-18 2004-03-03 Powderject Vaccines, Inc. Vaccine composition
DE10143490C2 (de) * 2001-09-05 2003-12-11 Gsf Forschungszentrum Umwelt Rekombinantes MVA mit der Fähigkeit zur Expression von HCV Struktur-Antigenen
CA2500215C (en) * 2002-09-27 2012-02-28 Powderject Research Limited Nucleic acid coated particles
US7335359B2 (en) 2003-02-06 2008-02-26 Tripep Ab Glycosylated specificity exchangers
KR20050099536A (ko) 2003-02-06 2005-10-13 트리펩 아베 글리코실화된 특이성 교환체
JP2010505883A (ja) 2006-10-12 2010-02-25 ザ ユニバーシティー オブ クイーンズランド 免疫応答を調節するための組成物および方法
CN102245198B (zh) 2008-12-09 2016-08-17 辉瑞疫苗有限责任公司 IgE CH3肽疫苗
KR20130127547A (ko) 2009-07-30 2013-11-22 화이자 백신스 엘엘씨 항원성 타우 펩타이드 및 이의 용도
SG178447A1 (en) 2009-09-03 2012-03-29 Pfizer Vaccines Llc Pcsk9 vaccine
EP2575868A1 (en) 2010-06-07 2013-04-10 Pfizer Vaccines LLC Ige ch3 peptide vaccine
WO2012058715A1 (en) 2010-11-01 2012-05-10 University Of Technology, Sydney Immune-modulating agents and uses therefor
PT2672992T (pt) 2011-02-11 2020-07-27 Univ Pennsylvania Molécula de ácidos nucleicos codificando proteína nuclear do vírus da hepatite b e vacina compreendendo a mesma
WO2012131504A1 (en) 2011-03-02 2012-10-04 Pfizer Inc. Pcsk9 vaccine

Also Published As

Publication number Publication date
CY1105600T1 (el) 2010-07-28
JP2002528123A (ja) 2002-09-03
EP1119630A1 (en) 2001-08-01
DE69929470T2 (de) 2006-08-24
CA2349505A1 (en) 2000-05-11
ATE315658T1 (de) 2006-02-15
AU775939B2 (en) 2004-08-19
WO2000026385A9 (en) 2000-10-26
IL142980A0 (en) 2002-04-21
PT1119630E (pt) 2006-05-31
NZ512078A (en) 2004-01-30
EP1119630B1 (en) 2006-01-11
AU2022200A (en) 2000-05-22
ES2257879T3 (es) 2006-08-01
DE69929470D1 (de) 2006-04-06
WO2000026385A1 (en) 2000-05-11

Similar Documents

Publication Publication Date Title
DK1119630T3 (da) Nukleinsyrekonstruktioner til genetisk immunisering
DK0460076T3 (da) Genetisk manipulerede immunoglobuliner
FR17C1046I1 (fr) Nouvelles molecules b7-4 et leurs utilisations
ATE518956T1 (de) Expressionsvektoren zur stimulierung einer immunantwort und verfahren zu deren verwendung
DK1187852T3 (da) Ekspression og eksport af interferon-alpha-proteiner som Fc-fusionsproteiner
CY1106842T1 (el) Συνθεσεις του ανασυνδυασμενου nodavirus και μεθοδοι
CY1114047T1 (el) Νεοι φορεις εκφρασης και χρησεις αυτων
DK0880360T3 (da) Hidtil ukendte fremgangsmåder til vaccination og vacciner dertil, hvilke vacciner omfatter en nucleinsyre, der koder en første epitop, og et peptid, der indeholder en sekundær epitop
FI20070041A (fi) Parannettu rokote Flavivirusinfektioiden vastaiseen immuunisointiin
WO2000075358A3 (en) Mammalian toll homologues and uses thereof
WO2000063385A3 (en) Nucleic acid immunization
WO2002103015A3 (en) Abca10 transporter
ATE442858T1 (de) Nukleinsäureadjuvantien
EE05691B1 (et) Ekspressioonivektorid ja nende rakendused
ATE276277T1 (de) Monoklonale antikörper gegen antigene, die durch hämatopoietische helferzellen exprimiert werden
MXPA03010527A (es) Composicion de vacuna.
WO2002051237A3 (en) Helicobacter proteins, nucleic acids and uses thereof
WO2001094390A3 (en) 52906, 33408, and 12189, potassium channel family members and uses thereof
NO20012471L (no) Kaliumkanal-interaktorer og anvendelser derav
WO2000047227A3 (en) Mycobacterium tuberculosis, immunization
DK1328621T3 (da) 13245, en ny human proteinkinase af den myotoniske dystrofitype og anvendelser deraf
WO2002070691A3 (en) Abcg4 transporter and uses thereof
AU2001285204A1 (en) Atcr-1, a human acyltransferase and uses thereof
WO2002070692A3 (en) Abca9 transporter and uses thereof
WO2002070693A3 (en) Novel abca6 transporter and uses thereof